InnoCan Pharma Corporation
INNO
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -133.28% | 38.71% | -24.20% | 63.69% | 87.51% |
| Total Depreciation and Amortization | 14.29% | 20.00% | -2.70% | -8.11% | -2.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -146.55% | -99.67% | 33.19% | -38.84% | -64.89% |
| Change in Net Operating Assets | 283.43% | 222.62% | 144.51% | -12.83% | 27.82% |
| Cash from Operations | 18.32% | 131.35% | 123.97% | 78.44% | 86.70% |
| Capital Expenditure | 38.89% | -6.67% | 30.00% | -14.29% | 14.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -98.55% | -- | 315.63% | 325.81% |
| Cash from Investing | -121.15% | -127.78% | 375.00% | 215.22% | 200.00% |
| Total Debt Issued | -29.69% | -- | -- | -- | -- |
| Total Debt Repaid | 66.67% | 50.00% | 19.05% | 0.00% | 0.00% |
| Issuance of Common Stock | -76.46% | -90.83% | -94.18% | -75.17% | -79.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -95.29% | -76.89% | -48.35% | -31.12% | -34.22% |
| Cash from Financing | -73.33% | -57.62% | -54.82% | -39.97% | -43.89% |
| Foreign Exchange rate Adjustments | 176.47% | 194.64% | 135.29% | 220.83% | -283.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -85.20% | 49.51% | 114.23% | 13.77% | 249.80% |